Self-immune liver is the abbreviation of autoimmune liver disease, and the statement that patients are fine for 30 years is not accurate. The prognosis of patients with autoimmune liver disease varies greatly, some patients can survive up to 30 years after active and regular treatment; some patients can have a poorer prognosis and a significantly shorter survival time due to the lack of active treatment and non-response to treatment. The majority of patients with self-exempted liver disease have a slow onset of disease, mild cases can have no clinical symptoms, after the disease progresses, there can be fatigue, abdominal distension, itching, jaundice, etc., and the active phase is accompanied by persistent fever, arthritis, rash and other extrahepatic manifestations, which can be treated with glucocorticosteroids (e.g., prednisone). Patients whose disease reaches a biochemical remission after the use of drugs generally have a better prognosis, with a 10-year overall survival rate of 80% to 93%. However, when the patient is combined with cirrhosis, unresponsive to treatment, or has recurrent episodes, the patient’s prognosis is poorer and survival is shortened. Patients with autoimmune liver should go to the hospital in time, and through active and regular treatment to slow down the progress of the disease and prolong the patient’s survival.